Further analysis revealed that there was no significant overall survival difference between patients who had high or low expression of HSF4 in glioblastoma, ovarian cancer, testicular germ cell cancer, and uterine carcinosarcoma (data not shown). This evidence concerns the gene HSF4 and ovarian cancer.